

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD

NALOX-1 PHARMACEUTICALS, LLC,

Petitioner,

v.

ADAPT PHARMA OPERATIONS LTD., AND  
OPIANT PHARMACEUTICALS, INC.

Patent Owners

CASE IPR2019-00685

U.S. Patent No. 9,211,253

Video deposition of STUART ALLEN JONES, Ph.D., held remotely via Zoom, on Friday, May 1, 2020, commencing at 8:06 a.m., before Kathleen McHugh, a Registered Professional Reporter, Certified Realtime Reporter, Certified Shorthand Reporter-NJ, License No. 30XI00180400, and Notary Public.

1 APPEARANCES:

2 ARENT FOX LLP

3 BY: RICHARD J. BERMAN, ESQUIRE (via Zoom)

4 Richard.berman@arentfox.com

5 BY: YELEE Y. KIM, ESQUIRE (via Zoom)

6 Yelee.kim@arentfox.com

7 1717 K Street, NW

8 Washington, DC 20006

9 202-857-6000

10 Counsel for Petitioner, Nalox-1

11 Pharmaceuticals, LLC

12

13 WILLIAMS & CONNOLLY LLP

14 BY: DAVID M. KRINSKY, ESQUIRE (via Zoom)

15 dkrinsky@wc.com

16 BY: JESSAMYN S. BERNIKER, ESQUIRE (via Zoom)

17 jberniker@wc.com

18 BY: ANA C. REYES, ESQUIRE (via Zoom)

19 areyes@wc.com

20 BY: ANTHONY H. SHEH, ESQUIRE (via Zoom)

21 asheh@wc.com

22 BY: YOULIN YUAN, ESQUIRE (via Zoom)

23 Yyuan@wc.com

24 725 Twelfth Street, NW

25 Washington, DC 20005

202-434-5000

Counsel for Patent Owner Adapt

Pharma Operations Limited

16

17 GREEN, GRIFFITH & BORG-BREEN LLP

18 BY: JESSICA TYRUS MACKAY, ESQUIRE (via Zoom)

19 jmackay@greengriffith.com

20 676 North Michigan Avenue, Suite 3900

21 Chicago, Illinois 60611

22 313-883-8000

23 Counsel for Patent Owners Adapt

24 Pharma Operations Ltd., and

25 Opiant Pharmaceuticals, Inc.

21

22

23 ALSO PRESENT:

24 Martin Zinkel, Videographer (via Zoom)

25 Joshua Harris (via Zoom)

25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

EXAMINATION INDEX

Dr. Stuart Allen Jones

BY MR. BERMAN . . . . . 4

4	<p>1 VIDEOGRAPHER: We are now on the video                  2 record.                  3 This is the video deposition of                  4 Dr. Stuart Allen Jones, taken by plaintiff --                  5 petitioner, in the matter of Nalox-1                  6 Pharmaceuticals, LLC v. Adapt Pharma Operations                  7 Ltd., et al., hearing remotely with the deponent in                  8 Watford, United Kingdom, on Friday, May 1st, 2020,                  9 at 8:06 a.m.                  10 I am Martin Zinkel, the videographer.                  11 The court reporter is Kathy McHugh. We are from                  12 the firm of Advanced Depositions in Philadelphia,                  13 Pennsylvania.                  14 Counsel will be noted on -- the                  15 appearances will be noted on the transcript, and                  16 the reporter will now swear in the witness.                  17 STUART ALLEN JONES, Ph.D., having been                  18 duly sworn, was examined and testified as follows:                  19 EXAMINATION                  20 BY MR. BERMAN:                  21 Q. Hello again, Dr. Jones. My name again                  22 is Rich Berman. I'm counsel for petitioner,                  23 Nalox-1 Pharmaceuticals, LLC.                  24 Let's turn to Exhibit 2300, your                  25 Supplemental Declaration, just the cover page,</p>	6	<p>1 is oxidative degradation, but there are others.                  2 And I cited in my first report that also naloxone                  3 is prone to photoinstability issues, i.e.,                  4 degradation under light.                  5 Q. If we can go to Nalox 1201, the                  6 Donovan Supplemental Declaration, and paragraph 15.                  7 And you can blow up up until the line                  8 there.                  9 Great.                  10 It says, Wyse discloses that                  11 formulations 7, 9, 14 and 14A contained, quote, an                  12 additional degradant, unquote, one that was not                  13 reported as being found in at least some of the                  14 other disclosed formulations. Since these                  15 formulations were pH adjusted, quote, to accelerate                  16 degradation, unquote, of the naloxone -- and                  17 there's a citation given there -- a Formulator POSA                  18 would have considered that, if the, quote,                  19 additional degradant, unquote, was a naloxone                  20 degradant, it would likely be an oxidation                  21 degradant.                  22 Do you see that?                  23 A. Yes.                  24 MR. KRINSKY: And I'd just like to                  25 note, you only have part of the paragraph on the</p>
5	<p>1 page 1.                  2 And this is the declaration that you                  3 submitted for the '747 patent.                  4 Do you see that?                  5 A. Yes.                  6 Q. And my understanding is that you                  7 submitted this same substantive declaration in all                  8 three IPRs; is that correct?                  9 A. Yes, I believe they're identical.                  10 Q. Okay. If we can go to paragraph 12.                  11 I don't have the page number in front of me.                  12 Oh, there you go. Good.                  13 It starts off --                  14 You can just blow up that paragraph.                  15 It starts off saying, Dr. Donovan                  16 limited the analysis in her second declaration to                  17 oxidative degradation of naloxone.                  18 Do you see that?                  19 A. Yes.                  20 Q. So sitting here today, you don't know                  21 of any mechanism for degradation of naloxone other                  22 than oxidative degradation, correct?                  23 A. I understand that the degradation of                  24 naloxone is a complex process, and it can occur by                  25 many different mechanisms. One of those mechanisms</p>	7	<p>1 screen. I just wanted to make sure Dr. Jones knew                  2 that he could ask Martin to put up what he needs to                  3 put up if he'd like to look at something else.                  4 BY MR. BERMAN:                  5 Q. Do you agree with Dr. Donovan's                  6 opinion that a POSA would have considered it likely                  7 that the naloxone degradant was an oxidation                  8 degradant?                  9 THE WITNESS: If you could just do --                  10 Martin, I still have to look at the full page,                  11 please. (Witness reviews document.)                  12 Could I just look at the next page of                  13 the document as well, please. (Witness reviews                  14 document.)                  15 If you can go back to the previous                  16 page, please. (Witness reviews document.)                  17 And can I have the question?                  18 BY MR. BERMAN:                  19 Q. Yes. Do you need me to repeat the                  20 question? Okay.                  21 The question is, do you agree with                  22 Dr. Donovan's opinion that a POSA would have                  23 considered it likely that the naloxone degradant                  24 was an oxidation degradant?                  25 A. The POSA would have read Wyse and</p>

8	<p>1 would have understood from Wyse that benzalkonium                  2 chloride caused the degradation of naloxone.                  3 They would have read Wyse and                  4 understood Wyse in the wider context of the                  5 literature and understand this was a valid                  6 proposition from Wyse's data and what Wyse actually                  7 said.                  8 Wyse identified an additional                  9 degradant of four formulations containing                  10 benzalkonium chloride. And, therefore, POSA would                  11 have read Wyse and understood that Wyse showed that                  12 benzalkonium chloride caused naloxone degradation.                  13 The POSA would not need to understand                  14 the mechanism by which that would occur because                  15 they would have read Wyse and understood Wyse from                  16 what Wyse said and what Wyse did.                  17 Wyse removed benzalkonium chloride in                  18 the formulations after finding it caused                  19 instability in the formulations with respect to                  20 naloxone, and, therefore, the POSA would have                  21 followed Wyse's teaching away from using                  22 benzalkonium chloride in the formulation and would                  23 not go on to think about the mechanism of                  24 degradation.                  25 Q. But do you agree with Dr. Donovan's</p>	10	<p>1 stable. The POSA would not go on to consider the                  2 mechanism by which that occurred.                  3 MR. BERMAN: If we can go to Wyse --                  4 that's Nalox 1007.                  5 MR. KRINSKY: I believe you said Nalox                  6 1007.                  7 MR. BERMAN: Nalox 1007. That's just                  8 the exhibit number. Thanks.                  9 PDF page 22, we're going to look at                  10 Example 5 on columns 26 and 27.                  11 If you could zoom in on where it says                  12 Example 5 above where you are a bit. Right there.                  13 Yes.                  14 No. Down. Down. Around line 20.                  15 Yes, there you go. That's fine.                  16 BY MR. BERMAN:                  17 Q. Okay. So I'm looking at Wyse Example                  18 5 and specifically at -- I'm going to just read                  19 from a couple of places and then ask you a couple                  20 of questions.                  21 Around line 29, it says, The                  22 formulations were at pH 5.0 to accelerate                  23 degradation.                  24 Do you see that?                  25 A. Yes.</p>
9	<p>1 opinion that a POSA would have considered it likely                  2 that the naloxone degradant was an oxidation                  3 degradant?                  4 MR. KRINSKY: Objection. Asked and                  5 answered.                  6 THE WITNESS: The POSA would have read                  7 Wyse and understood from Wyse that benzalkonium                  8 chloride caused naloxone degradation.                  9 Wyse produced a series of experiments                  10 whereby he tested naloxone's compatibility in a                  11 series of different intranasal formulations, and he                  12 showed from that series of experiments that,                  13 indeed, benzalkonium chloride caused naloxone                  14 degradation.                  15 He identified an additional naloxone                  16 degradation peak in four formulations which                  17 contained benzalkonium chloride and went on to                  18 state in a number of places in Wyse's patent that                  19 benzalkonium chloride caused the degradation of                  20 naloxone.                  21 The POSA would have read this and read                  22 what Wyse did subsequent to defining this finding                  23 in that he removed benzalkonium chloride from his                  24 subsequent formulation testing and went on to make                  25 an intranasal formulation that was chemically</p>	11	<p>1 Q. And then going on -- if you can leave                  2 that up, and then go on to the next column, 27.                  3 And then just go from the top down to                  4 about line 30.                  5 Yep. Perfect.                  6 And here around line 20, it says,                  7 Increasing the pH of the solution accelerated the                  8 degradation of naloxone HCL resulting in the                  9 formation of a major degradant at a relative                  10 retention time, RRT, of 0.52. However, it was                  11 found that decreasing the pH minimizes the                  12 formation of potential oxidative degradants.                  13 Do you see that?                  14 A. Yes.                  15 Q. So in this Example 5 test, Wyse                  16 increased the pH of the solution to accelerate the                  17 degradation of naloxone, correct?                  18 MR. KRINSKY: Object to the form of                  19 the question.                  20 THE WITNESS: (Witness reviews                  21 document.)                  22 Could you reask the question, please?                  23 BY MR. BERMAN:                  24 Q. Sure.                  25 In this example, Wyse increased the pH</p>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.